While Veracyte Inc has overperformed by 1.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -32.30%, with highs and lows ranging from $47.32 to $19.73, whereas the simple moving average fell by -23.16% in the last 200 days.
On March 20, 2025, Craig Hallum started tracking Veracyte Inc (NASDAQ: VCYT) recommending Buy. A report published by Goldman on December 05, 2024, Downgraded its rating to ‘Neutral’ for VCYT. Wolfe Research also rated VCYT shares as ‘Outperform’, setting a target price of $50 on the company’s shares in an initiating report dated November 15, 2024. UBS Initiated an Buy rating on October 16, 2024, and assigned a price target of $43. Guggenheim initiated its ‘Buy’ rating for VCYT, as published in its report on October 10, 2024. Needham’s report from February 23, 2024 suggests a price prediction of $33 for VCYT shares, giving the stock a ‘Buy’ rating. Raymond James also rated the stock as ‘Mkt Perform’.
Analysis of Veracyte Inc (VCYT)
Further, the quarter-over-quarter increase in sales is 18.20%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Veracyte Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 2.86% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.78, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and VCYT is recording an average volume of 1.01M. On a monthly basis, the volatility of the stock is set at 3.66%, whereas on a weekly basis, it is put at 3.16%, with a loss of -0.04% over the past seven days. Furthermore, long-term investors anticipate a median target price of $41.90, showing growth from the present price of $26.81, which can serve as yet another indication of whether VCYT is worth investing in or should be passed over.
How Do You Analyze Veracyte Inc Shares?
A leading company in the Diagnostics & Research sector, Veracyte Inc (VCYT) is based in the USA. When comparing Veracyte Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 63.91, there is a growth in quarterly earnings of 453.41%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.52%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 108.03% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VCYT shares are owned by institutional investors to the tune of 108.03% at present.
